ILAb Co., Ltd.
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending oral doses of IA-14069 in healthy subjects and in patients with RA on stable dosese of MTX, with preliminary assessment of efficacy in RA patients.
Inclusion Criteria: 1. Sex : Males or females; females may be of childbearing potential, of nonchildbearing potential, or postmenopausal. 2. Age : 18 to 55 years, inclusive, for healthy subjects in Part 1 and 18 to 70 years, inclusive, for RA patients in Part 2, at screening. 3. Body mass index (BMI) : 18 to 32 kg/m2, inclusive, for healthy subjects in Part 1 and 18 to 40 kg/m2, inclusive, for RA patients in Part 2, at screening. 4. Weight : ≥ 50 kg, inclusive, at screening. 5. Status : Healthy subjects for Part 1 and RA patients for Part 2. 6. At screening, females must not be pregnant or la…
IA-14069 for oral administration.
Placebo for oral administration.
Methotrexate for oral or SC administration.
Methotrexate for oral administration.
Arctuva estimate
Verify or correct the compensation shown for this listing.